1. Kang MI, Lee WY, Oh KW, Han JH, Song KH, Cha BY, et al. The short-term changes of bone mineral metabolism following bone marrow transplantation. Bone 2000;26:275-9.
[CROSSREF] [PUBMED]
2. Baek KH, Oh KW, Lee WY, Tae HJ, Rhee EJ, Han JH, et al. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism. Bone 2006;39:1352-60.
[CROSSREF] [PUBMED]
3. Baek KH, Kang MI. Biomarkers of bone and mineral metabolism following bone marrow transplantation. Adv Clin Chem 2009;49:99-120.
[PUBMED]
4. Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 2001;7:257-64.
[CROSSREF] [PUBMED]
5. Lee WY, Cho SW, Oh ES, Oh KW, Lee JM, Yoon KH, et al. The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 2002;87:329-35.
[CROSSREF] [PUBMED]
6. Kashyap A, Kandeel F, Yamauchi D, Palmer JM, Niland JC, Molina A, et al. Effects of allogeneic bone marrow transplantation on recipient bone mineral density: a prospective study. Biol Blood Marrow Transplant 2000;6(3A):344-51.
[CROSSREF] [PUBMED]
7. Valimaki MJ, Kinnunen K, Volin L, Tahtela R, Loyttyniemi E, Laitinen K, et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999;23:355-61.
[CROSSREF] [PUBMED]
8. Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000;6(2A):165-74.
[CROSSREF] [PUBMED]
9. Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood 2004;103:3635-43.
[CROSSREF] [PUBMED]
10. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, et al. The role of dickkopf-1 in bone development, homeostasis, and disease. Blood 2009;113:517-25.
[CROSSREF] [PUBMED] [PMC]
11. Schupbach D, Comeau-Gauthier M, Harvey E, Merle G. Wnt modulation in bone healing. Bone 2020;138:115491.
[CROSSREF] [PUBMED]
12. Moorer MC, Riddle RC. Regulation of osteoblast metabolism by Wnt signaling. Endocrinol Metab (Seoul) 2018;33:318-30.
[CROSSREF] [PUBMED] [PMC]
13. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
[CROSSREF] [PUBMED]
14. Huang Y, Liu L, Liu A. Dickkopf-1: current knowledge and related diseases. Life Sci 2018;209:249-54.
[CROSSREF] [PUBMED]
15. Morvan F, Boulukos K, Clement-Lacroix P, Roman Roman S, Suc-Royer I, Vayssiere B, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006;21:934-45.
[CROSSREF] [PUBMED]
16. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006;39:754-66.
[CROSSREF] [PUBMED]
17. Hurson CJ, Butler JS, Keating DT, Murray DW, Sadlier DM, O’Byrne JM, et al. Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis. BMC Musculoskelet Disord 2007;8:12.
[CROSSREF] [PUBMED] [PMC]
18. Thiele S, Ziegler N, Tsourdi E, De Bosscher K, Tuckermann JP, Hofbauer LC, et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res 2012;27:2242-50.
[CROSSREF] [PUBMED]
19. Wang FS, Ko JY, Lin CL, Wu HL, Ke HJ, Tai PJ. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss: a histomorphological study in ovariectomized rats. Bone 2007;40:485-92.
[CROSSREF] [PUBMED]
20. Jemtland R, Holden M, Reppe S, Olstad OK, Reinholt FP, Gautvik VT, et al. Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res 2011;26:1793-801.
[CROSSREF] [PUBMED]
21. Reppe S, Refvem H, Gautvik VT, Olstad OK, Hovring PI, Reinholt FP, et al. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. Bone 2010;46:604-12.
[CROSSREF] [PUBMED]
22. Fassio A, Adami G, Benini C, Vantaggiato E, Saag KG, Giollo A, et al. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone 2019;123:191-5.
[CROSSREF] [PUBMED]
23. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:348-71.
[CROSSREF] [PUBMED]
24. Kendler DL, Body JJ, Brandi ML, Broady R, Cannata-Andia J, Cannata-Ortiz MJ, et al. Bone management in hematologic stem cell transplant recipients. Osteoporos Int 2018;29:2597-610.
[CROSSREF] [PUBMED]
25. McClune BL, Majhail NS. Osteoporosis after stem cell transplantation. Curr Osteoporos Rep 2013;11:305-10.
[CROSSREF] [PUBMED]
26. Brown JP. Long-term treatment of postmenopausal osteoporosis. Endocrinol Metab (Seoul) 2021;36:544-52.
[CROSSREF] [PUBMED] [PMC]
27. Jeong C, Kim HJ, Lee S, Kang MI, Ha J. Effect of denosumab on bone mineral density of hematopoietic stem cell transplantation recipients. Int J Endocrinol 2020;2020:3410921.
[CROSSREF] [PUBMED] [PMC]
28. Vega D, Maalouf NM, Sakhaee K. Clinical review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007;92:4514-21.
[PUBMED]
29. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
[CROSSREF] [PUBMED]
30. Boppart MD, Kimmel DB, Yee JA, Cullen DM. Time course of osteoblast appearance after in vivo mechanical loading. Bone 1998;23:409-15.
[CROSSREF] [PUBMED]
31. Morse A, Ko FC, McDonald MM, Lee LR, Schindeler A, van der Meulen MC, et al. Increased anabolic bone response in Dkk1 KO mice following tibial compressive loading. Bone 2020;131:115054.
[CROSSREF] [PUBMED]